Anocca Raises $46M to Advance Clinical Trial Targeting Pancreatic Cancer

Anocca AB (Anocca), a clinical-stage T-cell immunotherapy company, raised SEK ~440 million (USD ~46 million) in financing. Mellby Gård led the financing with strong support from AMF, Ramsbury, and existing shareholders, alongside new investors.

The additional capital will be used to drive the continued progress of VIDAR-1, Anocca’s gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca’s preclinical pipeline.

Recruitment is now open for Phase I of the multi-center trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany, and the Netherlands.

Reagan Jarvis, co-founder and CEO of Anocca, said, “We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.”